ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ripretinib

Also written as “Ripretinib” and “DCC-2618”.

Its studies are mostly in Gastrointestinal Stromal Tumors, led by 2 companies.

Drug pageRipretinib: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 20, 20179 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ono Pharmaceutical73 open or runningphase 3since Nov 20, 2017Oct 5, 2015Dec 2027phase 3 · NCT05734105
Zai Labits history only20 open or runningphase 2since Feb 21, 2020Feb 21, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ono Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 5, 2015First study: phase 1 study in Gastrointestinal Stromal TumorsFirst studyNCT02571036 · 282 enrolled · United States, Canada, Germany and more
  2. Nov 20, 2017Phase 3 study in Gastrointestinal Stromal TumorsNCT03353753 · 129 enrolled · United States, Australia, Belgium and more
  3. Jun 9, 2018Named ripretinibINNProposed as its International Nonproprietary Name in WHO's List 119 · before, DCC-2618
  4. Sep 13, 2018Phase 3 study in Gastrointestinal Stromal TumorsNCT03673501 · 453 enrolled · United States, Argentina, Australia and more
  5. Aug 24, 2020Phase 1 study in Gastrointestinal Stromal TumorsNCT04530981 · 13 enrolled · United States
  6. Sep 20, 2021Phase 2 study in Gastrointestinal Stromal TumorsNCT05080621
  7. Feb 8, 2023Phase 3 study in Gastrointestinal Stromal TumorsNCT05734105 · 54 enrolled · United States, Australia, Brazil and more
  8. May 25, 2026Phase 1 study in Gastrointestinal Stromal TumorsNCT07618377 · 10 planned · Japan

Ahead

  1. Dec 2027Primary completion: phase 3 study in Gastrointestinal Stromal TumorsNCT05734105
  2. Feb 2028Primary completion: phase 1 study in Gastrointestinal Stromal TumorsNCT07618377

TargetBeta

KIT →PDGFRA →read by rule
“An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), ”NCIt, by rule
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38

Studies

All 7 Ono Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07618377Gastrointestinal Stromal Tumors · Japan1RecruitingFeb 202810
NCT05734105Gastrointestinal Stromal Tumors · United States, Australia, Brazil and more3Active, not recruitingDec 202754
NCT05080621Gastrointestinal Stromal Tumors2WithdrawnNov 20250
NCT04530981Gastrointestinal Stromal Tumors · United States1CompletedNov 16, 202313
NCT03673501Gastrointestinal Stromal Tumors · United States, Argentina, Australia and more3Active, not recruitingSep 1, 2021453
NCT03353753Gastrointestinal Stromal Tumors · United States, Australia, Belgium and more3CompletedMay 31, 2019129
NCT02571036Gastrointestinal Stromal Tumors · United States, Canada, Germany and more1CompletedApr 29, 2022282

How it is read

Names in the registry

  • “Ripretinib”, 5 entries
  • “DCC-2618”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.